Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer The ACHIEVE Phase 3 Randomized Clinical Trial

被引:76
作者
Yoshino, Takayuki [1 ]
Yamanaka, Takeharu [2 ]
Oki, Eiji [3 ]
Kotaka, Masahito [4 ]
Manaka, Dai [5 ]
Eto, Tetsuya [6 ]
Hasegawa, Junichi [7 ]
Takagane, Akinori [8 ]
Nakamura, Masato [9 ]
Kato, Takeshi [10 ]
Munemoto, Yoshinori [11 ]
Takeuchi, Shintaro [12 ]
Bando, Hiroyuki [13 ]
Taniguchi, Hiroki [14 ]
Gamoh, Makio [15 ]
Shiozawa, Manabu [16 ]
Mizushima, Tsunekazu [17 ]
Saji, Shigetoyo [18 ]
Maehara, Yoshihiko [18 ]
Ohtsu, Atsushi [1 ]
Mori, Masaki [3 ]
机构
[1] Natl Canc Ctr Hosp East, Chiba, Japan
[2] Yokohama City Univ, Sch Med, Yokohama, Kanagawa, Japan
[3] Kyushu Univ, Grad Sch Med Sci, Fukuoka, Japan
[4] Sano Hosp, Kobe, Hyogo, Japan
[5] Kyoto Katsura Hosp, Kyoto, Japan
[6] Tsuchiura Kyodo Gen Hosp, Ibaraki, Japan
[7] Osaka Rosai Hosp, Osaka, Japan
[8] Hakodate Goryoukaku Hosp, Hakodate, Hokkaido, Japan
[9] Aizawa Hosp, Nagano, Japan
[10] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan
[11] Fukui Ken Saiseikai Hosp, Fukui, Japan
[12] Teine Keijinkai Hosp, Sapporo, Hokkaido, Japan
[13] Ishikawa Prefectural Cent Hosp, Kanazawa, Ishikawa, Japan
[14] Kyoto Second Red Cross Hosp, Kyoto, Japan
[15] Osaki Citizen Hosp, Osaki, Miyagi, Japan
[16] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[17] Osaka Univ, Grad Sch Med, Osaka, Japan
[18] Japanese Fdn Multidisciplinary Treatment Canc, Tokyo, Japan
关键词
QUALITY-OF-LIFE; STAGE-II; 1ST-LINE TREATMENT; MODIFIED FOLFOX6; LEUCOVORIN; FLUOROURACIL; THERAPY; CAPECITABINE; COMBINATION; 5-FLUOROURACIL;
D O I
10.1001/jamaoncol.2019.2572
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IMPORTANCE Oxaliplatin-based chemotherapy is associated with debilitating peripheral sensory neuropathy (PSN) for patients with stage Ill colon cancer. OBJECTIVE To assess disease-free survival (DFS) and long-lasting PSN in patients treated with 3 vs 6 months of adjuvant oxaliplatin-based chemotherapy. DESIGN, SETTING, AND PARTICIPANTS An open-label, multicenter, phase 3 randomized clinical trial of 1313 Asian patients with stage III colon cancer was conducted investigating the noninferiority of 3 vs 6 months of adjuvant oxaliplatin-based chemotherapy. From August 1, 2012, to June 30, 2014, participants were randomized to the 2 treatment groups. Data were analyzed from July 2017 to June 2018. INTERVENTIONS Patients were randomized to receive 3 or 6 months of adjuvant chemotherapy. The choice of chemotherapy regimen, with the drugs modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or capecitabine plus oxaliplatin (CAPDX), was at the discretion of the treating physician. MAIN OUTCOMES AND MEASURES The primary outcome was DFS. Secondary end points included the evaluation of PSN for up to 3 years and overall survival. RESULTS Of the 1313 patients (651 were women and mean age was 66 [range, 28-85] years) enrolled and randomized, 22 were not treated because 10 were unable to begin treatment within 2 weeks of enrollment, 7 withdrew their consent, and 5 were not treated for various other reasons. Of 1291 patients treated (650 in the 3-month arm and 641 in the 6-month arm), 969 (75%) received the chemotherapy drug CAPDX. The hazard ratio (HR) for DFS of the 3-month arm compared with the 6-month arm was 0.95 (95% CI, 0.76-1.20). Hazard ratios were 1.07 (95% CI, 0.71-1.60) and 0.90 (95% CI, 0.68-1.20) for the drugs mFOLFOX6 and CAPDX, and 0.81(95% CI, 0.53-1.24) and 1.07 (95% CI. 0.81-1.40) for patients with low-risk disease (TNM classification stages T1-3 and N1) and high-risk disease (stages T4 or N2), respectively. The rates of any grade of PSN lasting for 3 years in the 3-month vs 6-month treatment arms were 9.7% vs 24.3% ( P < .001). Incidence of PSN lasting for 3 years was significantly lower for patients treated with CAPDX than for patients treated with mFOLFOX6 in both the 3-month (7.9% vs 15.7%; P = .04) and 6-month arms (21,0% vs 34.1%; P = .02). CONCLUSIONS AND RELEVANCE The incidence of long-lasting PSN was significantly lower for 3 months than for 6 months of therapy, and significantly lower for treatment with the drug CAPDX than with mFOLFOX6. Since the shortened therapy duration did not compromise outcomes, a 3-month course of CAPDX may be the most appropriate treatment option, particularly for patients with low-risk disease.
引用
收藏
页码:1574 / 1581
页数:8
相关论文
共 26 条
[1]   Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 [J].
Allegra, Carmen J. ;
Yothers, Greg ;
O'Connell, Michael J. ;
Sharif, Saima ;
Petrelli, Nicholas J. ;
Colangelo, Linda H. ;
Atkins, James N. ;
Seay, Thomas E. ;
Fehrenbacher, Louis ;
Goldberg, Richard M. ;
O'Reilly, Seamus ;
Chu, Luis ;
Azar, Catherine A. ;
Lopa, Samia ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :11-16
[2]   Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer [J].
Allegra, Carmen J. ;
Yothers, Greg ;
O'Connell, Michael J. ;
Sharif, Saima ;
Colangelo, Linda H. ;
Lopa, Samia H. ;
Petrelli, Nicholas J. ;
Goldberg, Richard M. ;
Atkins, James N. ;
Seay, Thomas E. ;
Fehrenbacher, Louis ;
O'Reilly, Seamus ;
Chu, Luis ;
Azar, Catherine A. ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3385-3390
[3]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[4]   Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen [J].
André, T ;
Bensmaine, MA ;
Louvet, C ;
François, E ;
Lucas, V ;
Desseigne, F ;
Beerblock, K ;
Bouché, O ;
Carola, E ;
Merrouche, Y ;
Morvan, F ;
Dupon-André, G ;
de Gramont, A .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3560-3568
[5]   Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial [J].
Andre, Thierry ;
Vernerey, Dewi ;
Mineur, Laurent ;
Bennouna, Jaafar ;
Desrame, Jerome ;
Faroux, Roger ;
Fratte, Serge ;
de Larauze, Marine Hug ;
Paget-Bailly, Sophie ;
Chibaudel, Benoist ;
Bez, Jeremie ;
Dauba, Jerome ;
Louvet, Christophe ;
Lepere, Celine ;
Dupuis, Olivier ;
Becouarn, Yves ;
Mabro, May ;
Egreteau, Joelle ;
Bouche, Olivier ;
Deplanque, Gael ;
Ychou, Marc ;
Galais, Marie Pierre ;
Ghiringhelli, Francois ;
Dourthe, Louis Marie ;
Bachet, Jean-Baptiste ;
Khalil, Ahmed ;
Bonnetain, Franck ;
de Gramont, Aimery ;
Taieb, Julien .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15) :1469-+
[6]   Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].
Andre, Thierry ;
Boni, Corrado ;
Navarro, Matilde ;
Tabernero, Josep ;
Hickish, Tamas ;
Topham, Clare ;
Bonetti, Andrea ;
Clingan, Philip ;
Bridgewater, John ;
Rivera, Fernando ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116
[7]   Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients [J].
Argyriou, A. A. ;
Velasco, R. ;
Briani, C. ;
Cavaletti, G. ;
Bruna, J. ;
Alberti, P. ;
Cacciavillani, M. ;
Lonardi, S. ;
Santos, C. ;
Cortinovis, D. ;
Cazzaniga, M. ;
Kalofonos, H. P. .
ANNALS OF ONCOLOGY, 2012, 23 (12) :3116-3122
[8]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[9]   Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer [J].
Giacchetti, S ;
Perpoint, B ;
Zidani, R ;
Le Bail, N ;
Faggiuolo, R ;
Focan, C ;
Chollet, P ;
Llory, JF ;
Letourneau, Y ;
Coudert, B ;
Bertheaut-Cvitkovic, F ;
Larregain-Fournier, D ;
Le Rol, A ;
Walter, S ;
Adam, R ;
Misset, JL ;
Lévi, F .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :136-147
[10]   Duration of Adjuvant Chemotherapy for Stage III Colon Cancer [J].
Grothey, A. ;
Sobrero, A. F. ;
Shields, A. F. ;
Yoshino, T. ;
Paul, J. ;
Taieb, J. ;
Souglakos, J. ;
Shi, Q. ;
Kerr, R. ;
Labianca, R. ;
Meyerhardt, J. A. ;
Vernerey, D. ;
Yamanaka, T. ;
Boukovinas, I. ;
Meyers, J. P. ;
Renfro, L. A. ;
Niedzwiecki, D. ;
Watanabe, T. ;
Torri, V. ;
Saunders, M. ;
Sargent, D. J. ;
Andre, T. ;
Iveson, T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13) :1177-1188